DrugManagementForum.com

Stimulation tests for growth hormone

This is a discussion on Stimulation tests for growth hormone within the Managed Care Issues for Injectable Drugs forum, part of the Managed Care Drug Coverage category; Was there some sort of changes in GH guidelines back in 2005 or 2006 increasing the number of GH stimulation ...


Go Back   DrugManagementForum.com > Managed Care Drug Coverage > Managed Care Issues for Injectable Drugs

Register Help Members List Mark Forums Read

Rate This Thread - Stimulation tests for growth hormone.

Only registered members can vote. To rate this thread register here.

Reply

 

Thread Tools
  #1 (permalink)  
Old 08-05-2008, 04:45 PM
participant1's Avatar
Senior Contributor
 
Join Date: Feb 2008
Posts: 83
Default Stimulation tests for growth hormone

Was there some sort of changes in GH guidelines back in 2005 or 2006 increasing the number of GH stimulation tests from one to two? I'm seeing more denials of requests with only 1 test
Reply With Quote
  #2 (permalink)  
Old 08-07-2008, 06:29 PM
jacqueline.kostick's Avatar
Moderator
 
Join Date: May 2008
Posts: 32
Default Re: Stimulation tests for growth hormone

The most recent guidelines which cover the diagnosis and treatment of GH deficiency were released by the Endocrine Society in 2006. Additionally, other guidelines were published by NICE in 2005 and AACE in 2003.

Based on the 3 guidelines, only the NICE guidance specified that a GH deficiency diagnosis should be confirmed by 2 GH provocation tests. Both the Endocrine Society and AACE did not state a particular threshold for the number of provocative tests; however, specific exceptions were described in each guideline:
  • The Endocrine Society states that the presence of 3 or more deficiencies of the pituitary axes strongly suggests the presence of GHD, and in this context provocative testing is optional.
  • NICE only requires 1 GH test in children with defined CNS pathology, a history of irradiation, multiple pituitary hormone deficiency (MPHD) or a genetic defect affecting the GH axis.
  • AACE states that the combination of complete hypopituitarism and a low IGF-I concentration is sufficient evidence to approve the use of GH therapy; therefore, the need for dynamic testing is eliminated.

Sources
1. The Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. Chevy Chase, MD: Endocrine Society; 2006. Available at the following link Accessed August 7, 2008.

2. NHS. National Institute for Clinical Excellence. Guidance on the use of growth hormone (somatropin) in children with growth failure. June 2005. Available at the following link Accessed August 7, 2008.

3. AACE. Medical guidelines for clinical practice for growth hormone use in adults and children, 2003 update. Available at the following link Accessed August 7, 2008.
Reply With Quote
Reply


Thread Tools
Display Modes


Similar Threads

Thread Thread Starter Forum Replies Last Post
UK Doctors to Face Regular Tests of Competence industry_news Other Clinical Pharmacy News 0 07-24-2008 04:41 PM
Growth Hormone Therapy May Decrease Diabetes Risk in Girls With Turner Syndrome industry_news Other Clinical Pharmacy News 0 07-24-2008 08:29 AM
Growth hormone for a new member with cranial irradiation participant1 Managed Care Issues for Injectable Drugs 1 05-16-2008 03:07 PM
SPOTLIGHT: Biotech sector poised for growth industry_news Biotechnology News 0 04-01-2008 02:02 PM


© 2008 DrugManagementForumpowered by
Informaceutica - Drug Management Information Company

All times are GMT -4. The time now is 06:29 PM.